Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 18, 2014

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions
Basal Cell Carcinoma
Interventions
DRUG

ERIVEDGE

Trial Locations (17)

13885

Hôpital de la Timone, Marseille

21079

CHU Bocage, Dijon

25030

CHU de Besançon, Besançon

33075

Hôpital St André, Bordeaux

33604

Hôpital Haut-Lévêque, Pessac

34295

Hôpital Saint Eloi, Montpellier

35033

Hôpital Pontchaillou, Rennes

51100

Hôpital Robert Debré, Reims

54500

Hôpitaux de Brabois, Vandœuvre-lès-Nancy

59037

Clinique de Dermatologie, Lille

62321

CH de Boulogne sur mer, Boulogne-sur-Mer

63003

CHU - Hôpital d'Estaing, Clermont-Ferrand

69495

Centre hospitalier Lyon Sud, Pierre-Bénite

75018

Hôpital Bichat, Paris

75475

Hôpital Saint-Louis, Paris

92104

CHU Ambroise Paré, Paris

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT02667574 - Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC) | Biotech Hunter | Biotech Hunter